In a new clinical trial, a drug-induced an integrated immune response in the tumors of patients with cancer types that do not usually respond to immunotherapy, say, researchers.
According to the study, published in the journal Proceedings of the National Academy of Sciences, the team hopes the potential treatment might make such tumors more responsive to the class of drugs known as immune checkpoint inhibitors.
Follow NewsGram on Instagram to keep yourself updated.
“Checkpoint inhibitors release natural brakes on the immune system, freeing it to find and destroy cancer cells. But they generally have not been effective against cancer cells with low levels of genetic mutation,” said study author Tobias Janowitz from the University of Cambridge in the UK.
Cancer immunotherapies, which empower patients’ immune systems to eliminate tumors, are revolutionizing cancer treatment. Many patients respond well to these treatments, sometimes experiencing long-lasting remissions.
Follow NewsGram on Twitter to stay updated about the World news.
But some cancers remain difficult to treat with immunotherapy, and expanding the impact of the approach is a high priority.
In this clinical trial, the research team interrupted that immunosuppressive pathway with a drug called plerixafor.
The drug was administered continuously by intravenous therapy (IV) for one week to 24 patients with either pancreatic cancer or colorectal cancer with a low tumor mutational burden.
Want to read more in Hindi? Checkout: ‘स्कैम 1992’ के लिए डायलॉग लिखना क्यों था चुनौतीपूर्ण?
All patients had advanced disease, and biopsies were collected from metastatic tumors before and after treatment.
When the team analyzed those patient samples, they found that critical immune cells had infiltrated the tumors during the time patients received plerixafor, including a cell type known to summon and organize key players in the anti-cancer response.
The finding was encouraging because the team detected changes that have also been observed in patients whose cancers responded well to checkpoint inhibitors, the authors wrote. (IANS)